RxDoctor Payments Data

Michael Snyder, MD

Colon & Rectal Surgery · Houston, TXNPI 1477564839

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (59.0%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 50.6% of the total. Reporting peaked in 2019 at $6,320 and has fallen 85.1% since, to $942 in 2025.

$23,612in general payments, 2019–2025

Across 137 payments — averaging $172.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$12K
  • Pacira Pharmaceuticals Incorporated$4K
  • Covidien LP$2K
  • THD America, Inc.$831
  • Medtronic$760
  • Baxter Healthcare$443
  • plus $4K from 33 others
$58,137in research payments, 2019–2025

Across 57 payments — averaging $1019.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$58K

What the payments were for

  • Consulting fees$13,93259%
  • Speaking & faculty fees$3,29514%
  • Food & beverage$6,38527%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,612 in reported general payments places this provider in the 80th percentile of 200 colon & rectal surgery providers in Texas.

See all colon & rectal surgery providers in Texas

Medicare billing

Part B allowed, 2024
$119,566
Medicare patients
262
Services billed
729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates129$8,013
Metronidazole37$337
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen38$213
Neomycin Sulfate27$165
Hydrocortisone35$142

Paid to pharmacies, not to this prescriber.

Other colon & rectal surgery in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →